Tepilamide fumarate manufacturers
|
| | Tepilamide fumarate Basic information |
| Product Name: | Tepilamide fumarate | | Synonyms: | Tepilamide fumarate;2-Butenedioic acid (2E)-, 1-[2-(diethylamino)-2-oxoethyl] 4-methyl ester;XP-23829;XP 23829,Tepilamide,XP23829,psoriasis,PPC-06,fumaric acid ester,inhibit,Tepilamide fumarate,Inhibitor,PPC06,PPC 06;Tepilamide fumarate, 10 mM in DMSO;(N,N-Diethylcarbamoyl)methyl methyl (2E)-but-2-ene-1,4-dioate | | CAS: | 1208229-58-6 | | MF: | C11H17NO5 | | MW: | 243.26 | | EINECS: | | | Product Categories: | | | Mol File: | 1208229-58-6.mol |  |
| | Tepilamide fumarate Chemical Properties |
| Boiling point | 347.5±22.0 °C(Predicted) | | density | 1.131±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: ≥ 125 mg/mL (513.85 mM) | | form | Solid | | pka | -1.04±0.70(Predicted) | | color | White to off-white |
| | Tepilamide fumarate Usage And Synthesis |
| Uses | Tepilamide fumarate (XP-23829; PPC-06) is an oral fumaric acid ester, acts as a proagent of Monomethyl Monomethyl fumarate (HY-103252), and is used in the research of moderate to severe chronic plaque psoriasis. Tepilamide fumarate can enhance the effectiveness of oncolytic viruses[1][2]. | | References | [1] Mrowietz U, et al. Tepilamide Fumarate (PPC-06) Extended Release Tablets in Patients with Moderate-to-Severe Plaque Psoriasis: Safety and Efficacy Results from the Randomized, Double-blind, Placebo-controlled AFFIRM Study. J Clin Aesthet Dermatol. 2022 Jan;15(1):53-58. PMID:35309277
[2] Akram Alwithenani, et al. Tepilamide Fumarate as a Novel Potentiator of Virus-Based Therapy. Viruses. 2024 Jun 5;16(6):920. DOI:10.3390/v16060920 |
| | Tepilamide fumarate Preparation Products And Raw materials |
|